Bimatoprost/Timolol Versus Travoprost/Timolol
Information source: Kasr El Aini Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma
Intervention: Ganfort (Drug); Duotrav (Drug)
Phase: N/A
Status: Completed
Sponsored by: Kasr El Aini Hospital Official(s) and/or principal investigator(s):
Tamer A Macky, MD FRCS, Principal Investigator, Affiliation: Cairo University
Summary
The purpose of this study is to compare 2 fixed combination medications in intraocular
pressure lowering.
Clinical Details
Official title: Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Percentage of drop of intraocular pressures from baseline.
Detailed description:
PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC)
fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.
METHODS: Patients with primary open angle glaucoma (POAG) were randomized to receive either
BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The
primary outcome measures were the mean change in IOP from baseline
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Glaucoma
Exclusion Criteria:
- No other ocular diseases
Locations and Contacts
Kasr El Aini Hospital, Cairo, Egypt
Additional Information
Starting date: January 2011
Last updated: March 1, 2012
|
